Molecular and immunophenotypic predictors of response to azacitidine (aza) as frontline therapy for acute myeloid leukemia (AML).

被引：0
|
作者：
Zimmerman, Michael Keith Alister
Grunwald, Michael Richard
Symanowski, James Thomas
Gerber, Jonathan Michael
机构：
[1] Levine Canc Inst, Charlotte, NC USA
[2] Levine Canc Inst, Carolinas HealthCare Syst, Charlotte, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.7024
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7024
引用
收藏
页数：4
相关论文
共 50 条
  • [41] AZACITIDINE FRONTLINE AND SALVAGE THERAPY FOR ACUTE MYELOID LEUKEMIA PATIENTS. CLINICAL EXPERIENCE AND DEVELOPMENT OF A NEW RISK SCORE
    Imbergamo, S.
    Visentin, A.
    Kostic, I.
    Scomazzon, E.
    Laurino, M.
    Lessi, F.
    Binotto, G.
    Gurrieri, C.
    Semenzato, G.
    Trentin, L.
    HAEMATOLOGICA, 2017, 102 : 75 - 76
  • [42] Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia
    D A Pollyea
    H E Kohrt
    L Gallegos
    M E Figueroa
    O Abdel-Wahab
    B Zhang
    S Bhattacharya
    J Zehnder
    M Liedtke
    J R Gotlib
    S Coutre
    C Berube
    A Melnick
    R Levine
    B S Mitchell
    B C Medeiros
    Leukemia, 2012, 26 : 893 - 901
  • [43] UPDATED RESULTS FROM A PHASE 2 STUDY OF PRACINOSTAT (P) IN COMBINATION WITH AZACITIDINE (AZA) IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
    Garcia-Manero, G.
    Atallah, E.
    Khaled, S.
    Arellano, M.
    Patnaik, M.
    Esquibel, V.
    Wood, K.
    Medeiros, B.
    HAEMATOLOGICA, 2015, 100 : 216 - 216
  • [44] Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia
    Pollyea, D. A.
    Kohrt, H. E.
    Gallegos, L.
    Figueroa, M. E.
    Abdel-Wahab, O.
    Zhang, B.
    Bhattacharya, S.
    Zehnder, J.
    Liedtke, M.
    Gotlib, J. R.
    Coutre, S.
    Berube, C.
    Melnick, A.
    Levine, R.
    Mitchell, B. S.
    Medeiros, B. C.
    LEUKEMIA, 2012, 26 (05) : 893 - 901
  • [45] Real-World Use of Azacitidine (AZA) and Venetoclax (VEN) in Acute Myeloid Leukemia (AML) in Frontline and Relapse/Refractory (R/R) Settings: Multicenter Study From French AURAML Group
    Heiblig, Mael
    Tavernier, Emmanuelle
    Requena, Gaspar Aspas
    Belhabri, Amine
    Mauz, Natacha
    Contejean, Adrien
    Pica, Gian-Matteo
    Carre, Martin
    Rocher, Clement
    Santana, Clemence
    Gross, Zofia
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S303 - S303
  • [46] Azacitidine in Acute Myeloid Leukemia: Comparison of Patients with AML-MRF Vs AML-NOS Enrolled in the Austrian Azacitidine Registry
    Pleyer, Lisa
    Burgstaller, Sonja
    Stauder, Reinhard
    Girschikofsky, Michael
    Linkesch, Werner
    Pfeilstoecker, Michael
    Autzinger, Eva Maria
    Tinchon, Christoph
    Sliwa, Thamer
    Lang, Alois
    Sperr, Wolfgang R.
    Geissler, Dietmar
    Krippl, Peter
    Voskova, Daniela
    Rossmann, Dieter H.
    Schlick, Konstantin
    Thaler, Josef
    Halter, Britta
    Machherndl-Spandl, Sigrid
    Theiler, Georg
    Valent, Peter
    Eckmuellner, Otto
    Greil, Richard
    BLOOD, 2014, 124 (21)
  • [47] Immunophenotypic profile of adult acute myeloid leukemia (AML): Analysis of 267 cases in Thailand
    Auewarakul, CU
    Promsuwicha, O
    U-pratya, Y
    Pattanapanyasat, K
    Issaragrisil, S
    ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY, 2003, 21 (03): : 153 - 160
  • [48] Molecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidine
    Desoutter, J.
    Gay, J.
    Berthon, C.
    Ades, L.
    Gruson, B.
    Geffroy, S.
    Plantier, I.
    Marceau, A.
    Helevaut, N.
    Fernandes, J.
    Bemba, M.
    Stalnikiewicz, L.
    Frimat, C.
    Labreuche, J.
    Nibourel, O.
    Roumier, C.
    Figeac, M.
    Fenaux, P.
    Quesnel, B.
    Renneville, A.
    Duhamel, A.
    Preudhomme, C.
    LEUKEMIA, 2016, 30 (06) : 1416 - 1418
  • [49] Molecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidine
    J Desoutter
    J Gay
    C Berthon
    L Ades
    B Gruson
    S Geffroy
    I Plantier
    A Marceau
    N Helevaut
    J Fernandes
    M Bemba
    L Stalnikiewicz
    C Frimat
    J Labreuche
    O Nibourel
    C Roumier
    M Figeac
    P Fenaux
    B Quesnel
    A Renneville
    A Duhamel
    C Preudhomme
    Leukemia, 2016, 30 : 1416 - 1418
  • [50] Efficacy and Safety of Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Patients Aged ≥75 Years with Acute Myeloid Leukemia (AML) in the Phase 3 AZA-AML-001 Study
    Seymour, John F.
    Buckstein, Rena
    Santini, Valeria
    Doehner, Hartmut
    Stone, Richard M.
    Minden, Mark D.
    Kuo, Ching-Yuan
    Ben-Yehuda, Dina
    Bargay, Joan
    Songer, Stephen
    Weaver, Jerry
    Beach, C. L.
    Dombret, Herve
    BLOOD, 2016, 128 (22)
12345